Effect of Unani medicine Habb-e-Hilteet in Zuâ??f al-IshtihÄ?â?? (Anorexia)

Clinical Validation of a Unani Pharmacopoeial Formulation - Habbe-Hilteet in Zuf al-lshtiha (Anorexia)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/12/016577

Enrollment

300

Registered

2018-12-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R630- Anorexia Health Condition 2: null- Zuâ??f al-IshtihÄ?â?? (Anorexia)

Interventions

Intervention1: Habb-e-Hilteet ( 500 md Tablet): One tablet twice daily orally with water one hour after meals for two weeks Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of any sex in the age group 19-65 years 2. Patients having Zuâ??f al-IshtihÄ?â?? (Anorexia)

Exclusion criteria

Exclusion criteria: 1. Patients having Anorexia nervosa 2. Patients having any systemic disease, chronic debilitating disease, T.B., Diabetes Mellitus etc. 3. Known cases of Hepatic, Renal or Cardiac Ailments 4. History of hypersensitivity to study drug or any of its ingredients. 5. History of addiction (Alcohol, Drugs) 6. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of Zuâ??f al-IshtihÄ?â?? (Anorexia)Timepoint: 2 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: At baseline and end of treatment ie 2 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026